Please login to the form below
atogepant
This page shows the latest atogepant news and features for those working in and with pharma, biotech and healthcare.
AbbVie submits migraine prevention drug to EMA for marketing authorisation
If approved, atogepant would be the first daily oral CGRP receptor antagonist migraine treatment for adults in Europe. ... Atogepant is an orally administered, CGRP receptor antagonist developed for the prevention of migraines.
Latest news
-
AbbVie shares positive phase 3 results for migraine drug Qulipta
The impact of chronic migraines on patients can be debilitating. AbbVie has announced results from its phase 3 PROGRESS trial evaluating Qulipta (atogepant) – a treatment for adult patients suffering from chronic ... AbbVie. He added: “We look
-
Allergan gets FDA nod for first oral CGRP drug for migraine
Meanwhile, Allergan also has an oral CGRP inhibitor in late-stage development for migraine prevention – called atogepant – and is expecting results in the second half of 2020. ... Atogepant is expected to account for the bulk of Allergan’s sales in
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Kite and Arcellx close multiple myeloma collaboration agreement
- The challenges of identifying rare diseases
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EU outlines measures to mitigate antibiotic shortage across Europe
- The challenges of identifying rare diseases
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- This month in 1917: A tale of two Mercks
PMHub
The Difference Collective
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...
Latest intelligence
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
